Drug updated on 11/4/2024
| Dosage Form | Injection (intravenous/subcutaneous; 50 mcg/mL, 100 mcg/mL, 500 mcg/mL) |
| Drug Class | Somatostatin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses
- Indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease
- Indicated for the treatment of profuse watery diarrhea associated with VIP-secreting tumors.
Latest News
Summary
- This summary is based on the review of eight systematic review(s)/meta-analysis(es). [1-8]
- Home injections of SSAs (lanreotide Autogel/Depot or octreotide LAR) in patients with acromegaly and NETs (neuroendocrine tumors) resulted in comparable disease control to healthcare-setting injections, with high treatment adherence reported in acromegaly patients receiving lanreotide at home.
- Patient preferences leaned towards LAN (lanreotide autogel/depot) over OCT LAR (octreotide long-acting release) in 4 out of 5 studies, with factors like fewer technical issues, reduced pain, better emotional quality, time savings, convenience, and greater independence influencing treatment experience.
- Combination therapy of SRLs and pegvisomant showed the highest effectiveness for IGF-1 control in acromegaly patients, with pegvisomant alone outperforming OCT LAR and LAN in unselected patients.
- The incidence of non-serious adverse events was similar between home and healthcare administration settings for somatostatin analog injections.
- Long-acting SSA therapy prior to imaging did not affect tumor uptake but decreased uptake in the liver and spleen without significant adverse effects.
- Studies primarily included patients with acromegaly, NETs, and MEN1-related pNENs, with findings indicating that SSA treatments, such as LAN and OCT, were effective and safe in both home and healthcare settings. LAN was preferred for patient experience over OCT LAR, and partially responsive patients showed effective IGF-1 control with combination therapy or pegvisomant monotherapy. Patients undergoing surgery for NETs experienced a high incidence of intraoperative carcinoid crisis, where prophylactic octreotide showed limited efficacy.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Sandostatin (octreotide acetate) Prescribing Information. | 2024 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Neuroendocrine tumor theranostics: an update and emerging applications in clinical practice. | 2021 | American Journal of Roentgenology |
| A pituitary society update to acromegaly management guidelines. | 2021 | Pituitary |
| Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. | 2021 | Journal of the National Comprehensive Cancer Network |
| Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. | 2020 | Expert Opinion on Pharmacotherapy |